Human lymphocyte vaccine adjuvant
US8088397B2 · kind B2 · utility
2Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 28, 2010 |
| Grant date | Jan 3, 2012 |
| Priority date | — |
| Expiry date | Jun 28, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55588
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.